- Home
- IFRX vs MOBX Comparison
IFRX vs MOBX Comparison
Compare IFRX & MOBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- MOBX
- Stock Information
- Founded
- IFRX 2007
- MOBX 2020
- Country
- IFRX Germany
- MOBX United States
- Employees
- IFRX N/A
- MOBX N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- MOBX
- Sector
- IFRX Health Care
- MOBX
- Exchange
- IFRX Nasdaq
- MOBX Nasdaq
- Market Cap
- IFRX 53.5M
- MOBX 43.8M
- IPO Year
- IFRX 2017
- MOBX N/A
- Fundamental
- Price
- IFRX $0.83
- MOBX $0.85
- Analyst Decision
- IFRX Strong Buy
- MOBX
- Analyst Count
- IFRX 4
- MOBX 0
- Target Price
- IFRX $7.75
- MOBX N/A
- AVG Volume (30 Days)
- IFRX 198.5K
- MOBX 634.9K
- Earning Date
- IFRX 08-07-2025
- MOBX 08-18-2025
- Dividend Yield
- IFRX N/A
- MOBX N/A
- EPS Growth
- IFRX N/A
- MOBX N/A
- EPS
- IFRX N/A
- MOBX N/A
- Revenue
- IFRX $191,224.00
- MOBX $10,692,000.00
- Revenue This Year
- IFRX N/A
- MOBX N/A
- Revenue Next Year
- IFRX $1,276.37
- MOBX N/A
- P/E Ratio
- IFRX N/A
- MOBX N/A
- Revenue Growth
- IFRX 54.36
- MOBX 450.28
- 52 Week Low
- IFRX $0.71
- MOBX $0.55
- 52 Week High
- IFRX $2.82
- MOBX $2.47
- Technical
- Relative Strength Index (RSI)
- IFRX 44.92
- MOBX 47.40
- Support Level
- IFRX $0.74
- MOBX $0.78
- Resistance Level
- IFRX $0.86
- MOBX $0.99
- Average True Range (ATR)
- IFRX 0.07
- MOBX 0.10
- MACD
- IFRX -0.00
- MOBX -0.02
- Stochastic Oscillator
- IFRX 44.02
- MOBX 16.82
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About MOBX Mobix Labs Inc.
Mobix Labs Inc. specializes in designing, developing, and selling components and systems for wireless and wired connectivity, radio frequency (RF) technologies, switching, and electromagnetic interference (EMI) filtering solutions. The company serves markets, including commercial, industrial, automotive, medical, aerospace, defense, and others.